SanBio Company Limited
Earnings Briefing
Announces 2Q of the fiscal year ending January 2027. Revenue is undisclosed; focuses on changes in costs centered on R&D expenses, with an improvement in operating loss. Outlines post-AQUGO (Auguo) launch adoption and strengthened supply chains, accelerated U.S. expansion, and a roadmap toward expanding indications for stroke.
Key Figures
- Business expenses: 1,909 million yen
- R&D expenses: 1,226 million yen
- Net income: ▲1,791 million yen
AI要約
Section heading
This earnings summary centers on the consolidated results for the 2Q of the fiscal year ending January 2027, outlining current revenue and cost items and the outlook for the second half. It emphasizes post-launch adoption of AQUGO domestically, stabilization of the supply framework, and promotion of regional medical collaboration as a foundation for future global expansion. It explains the reduction in losses due to delayed recognition of some R&D costs, and presents cost plans for H2 and efforts to secure cash position.
Second section heading
Looking ahead, the three pillars of a global leader strategy anchored in Japan as the mother base, domestic adoption of AQUGO with expanded U.S. deployment, and expanded indications for stroke are highlighted. It details the reinforcement of regional medical collaboration, integrated manufacturing and logistics, and concrete plans for clinical trial preparations and execution, outlining paths for starting trials and expanding partnerships from next year onward.
Revenue trend
Operating profit trend
Profit margin analysis
SanBio Company Limited
Company overview · Stock price · Financial data · All IR
